CervoMed Inc. (CRVO)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Biotechnology (Startups)	4.01M	9.74M	7.14M
Biotechnology (Startups) Growth	-58.86%	36.29%	-
Total	4.01M	9.74M	7.14M
Total Growth	-58.86%	36.29%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
United States	4.01M	9.74M	7.14M
United States Growth	-58.86%	36.29%	-
Total	4.01M	9.74M	7.14M
Total Growth	-58.86%	36.29%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 15, 2026

Data Sources Report a data error